surmount-1 trial tirzepatide weight loss nondiabetic non-diabetic obesity Effect of in trial. (BMI: body mass index; CI: surmount-1 trial tirzepatide – Tirzepatide after intensive lifestyle intervention – surmount-1 trial tirzepatide non-diabetic obesity

Similar side effects were observed with the D/D antagonist ecopipam

Researchers have also been investigating how the drug, and other GLP-1 drugs, could be used to treat obesity-related comorbidities, like cardiovascular disease and heart failure

If you experience nausea, dizziness, or digestive discomfort that disrupts your day or sleep, let your physician know

BPC-157 was administered at doses ranging from 10 micrograms per kilogram down to just 10 picograms per kilogram

It helps the body produce insulin and lower blood sugar levels

Clinical trials measured results over 72 weeks, so this is generally considered a long-term treatment rather than a quick fix